Sunesis Pharmaceuticals (FRA:RYIS) EV-to-Revenue : 584.45 (As of May. 12, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sunesis Pharmaceuticals's enterprise value is €63.71 Mil. Sunesis Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 was €0.11 Mil. Therefore, Sunesis Pharmaceuticals's EV-to-Revenue for today is 584.45.

The historical rank and industry rank for Sunesis Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:RYIS's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.37
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), Sunesis Pharmaceuticals's stock price is €16.275016. Sunesis Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was €0.12. Therefore, Sunesis Pharmaceuticals's PS Ratio for today is 135.63.

Sunesis Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Sunesis Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals EV-to-Revenue Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EV-to-Revenue

Get a 7-Day Free Trial

100.86

656.63

292.07

58.17

929.44

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
EV-to-Revenue	Get a 7-Day Free Trial															58.17	71.25	46.92	26.93	929.44

Competitive Comparison of Sunesis Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Sunesis Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunesis Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's EV-to-Revenue falls into.

Sunesis Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sunesis Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	63.705	/	0.109
	=	584.45

Sunesis Pharmaceuticals's current Enterprise Value is €63.71 Mil.
Sunesis Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.11 Mil.

Sunesis Pharmaceuticals (FRA:RYIS) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sunesis Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	16.275016	/	0.12
	=	135.63

Sunesis Pharmaceuticals's share price for today is €16.275016.
Sunesis Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.12.

Sunesis Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines